文献速递泌尿男性生殖肿瘤

22基因基因组分类器在复发性前列腺癌中的验证:NRG/RTOG 9601随机临床试验的辅助研究

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

该辅助研究利用NRG/RTOG 9601随机临床试验中根治性前列腺切除术后复发患者的标本,验证Decipher基因组分类器(GC)对远处转移(DM)的独立预后价值。中位随访13年,352例患者纳入最终分析。

要点

  • Decipher GC评分独立于年龄、Gleason评分、T分期等临床病理变量,与远处转移、前列腺癌特异性死亡和总生存相关。
  • GC评分较低与较高患者相比,比卡鲁胺对12年总生存的绝对效应较小(2.4% vs 8.9%)。
  • 在PSA<0.7 ng/mL接受早期挽救性放疗的男性中,比卡鲁胺的绝对效应分别为-7.8% vs 4.6%。

核心结论

  • Decipher GC评分与根治性前列腺切除术后生化复发患者的远处转移、前列腺癌特异性死亡和总生存独立相关。
  • 并非所有生化复发患者从挽救性放疗联合激素治疗中同等获益。

研究设计与样本

  • 辅助研究使用NRG/RTOG 9601随机临床试验(1998年3月至2003年3月)中根治性前列腺切除术后复发患者的标本。
  • 760例随机患者中486例生成GC评分,352例通过芯片质量控制纳入最终分析,中位随访13年。

主要发现

  • GC评分较低与较高患者相比,比卡鲁胺对12年OS的绝对效应较小(2.4% vs 8.9%)。
  • 在PSA<0.7 ng/mL接受早期sRT的男性中,比卡鲁胺的绝对效应为-7.8% vs 4.6%。

临床怎么用

  • Decipher GC可用于根治性前列腺切除术后生化复发患者,辅助识别远处转移高风险个体。
  • GC评分可能帮助判断哪些患者从挽救性放疗联合比卡鲁胺中获益更多。

局限性

  • 原计划分析未设定检验GC评分与治疗交互作用的效能。
  • GC评分仅从486/760例随机患者中生成,最终分析队列为352例。
  • 研究人群以白人为主(314/352,89.2%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with prostate cancer. OBJECTIVE: To validate the GC in the context of a randomized phase 3 trial. DESIGN, SETTING, AND PARTICIPANTS: This ancillary study used RP specimens from the phase 3 placebo-controlled NRG/RTOG 9601 randomized clinical trial conducted from March 1998 to March 2003. The specimens were centrally reviewed, and RNA was extracted from the highest-grade tumor available in 2019 with a median follow-up of 13 years. Clinical-grade whole transcriptomes from samples passing quality control were assigned GC scores (scale, 0-1). A National Clinical Trials Network-approved prespecified statistical plan included the primary objective of validating the independent prognostic ability of GC for DM, with secondary end points of prostate cancer-specific mortality (PCSM) and overall survival (OS). Data were analyzed from September 2019 to December 2019. INTERVENTION: Salvage radiotherapy (sRT) with or without 2 years of bicalutamide. MAIN OUTCOMES AND MEASURES: The preplanned primary end point of this study was the independent association of the GC with the development of DM. RESULTS: In this ancillary study of specimens from a phase 3 randomized clinical trial, GC scores were generated from 486 of 760 randomized patients with a median follow-up of 13 years; samples from a total of 352 men (median [interquartile range] age, 64.5 (60-70) years; 314 White [89.2%] participants) passed microarray quality control and comprised the final cohort for analysis. On multivariable analysis, the GC (continuous variable, per 0.1 unit) was independently associated with DM (hazard ratio [HR], 1.17; 95% CI, 1.05-1.32; P = .006), PCSM (HR, 1.39; 95% CI, 1.20-1.63; P < .001), and OS (HR, 1.17; 95% CI, 1.06-1.29; P = .002) after adjusting for age, race/ethnicity, Gleason score, T stage, margin status, entry prostate-specific antigen, and treatment arm. Although the original planned analysis was not powered to detect a treatment effect interaction by GC score, the estimated absolute effect of bicalutamide on 12-year OS was less when comparing patients with lower vs higher GC scores (2.4% vs 8.9%), which was further demonstrated in men receiving early sRT at a prostate-specific antigen level lower than 0.7 ng/mL (-7.8% vs 4.6%). CONCLUSIONS AND RELEVANCE: This ancillary validation study of the Decipher GC in a randomized trial cohort demonstrated association of the GC with DM, PCSM, and OS independent of standard clinicopathologic variables. These results suggest that not all men with biochemically recurrent prostate cancer after surgery benefit equally from the addition of hormone therapy to sRT. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00002874.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Feng FY, Huang HC, Spratt DE, et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33570548. doi:10.1001/jamaoncol.2020.7671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。